Immune Design Corporation

116 articles about Immune Design Corporation

• Merck Completes Tender Offer to Acquire Immune Design

  4/2/2019

  Merck, known as MSD outside the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Immune Design at a purchase price of $5.85 per share.

• Merck Begins Tender Offer to Acquire Immune Design

  3/5/2019

  Merck, known as MSD outside the United States and Canada, is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Immune Design.

• Merck to Acquire Immune Design

  2/21/2019

  Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer

• 

  Merck Acquires Immune Design for $300 Million in Cash

  2/21/2019

  Shares of Immune Design are skyrocketing in premarket trading today after Merck announced it will acquire the Seattle-based oncology company for $300 million in cash. Immune Design stock has shot up more than 310 percent to $5.83 in early trading.
• 

  Immune Design Abandons Cancer Vaccine Program, Drops 20% of Workforce at Two U.S. Locations

  10/18/2018

  The company, with sites in Seattle and South San Francisco, focuses on next-generation oncology therapeutics. It recently completed a portfolio review and decided to focus its energies and existing capital on G100 and abandoned its CMB305 program.

• Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update

  8/1/2018

  G100 advancing to late-stage development following FDA feedback

• 

  Why This Seattle Biotech Could be an M&A Target

  1/19/2018

  Immune Design is a clinical-stage immunotherapy company.

• Immune Design's Combination of G100 With KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

  12/11/2017

  These data were presented at the 59th American Society of Hematology (ASH) Annual meeting in Atlanta, Georgia on Sunday, December 10, 2017.

• Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update

  10/27/2017

  Management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 1, 2017.

• Immune Design Prices $80M Public Offering of Common Stock

  10/25/2017

  All of the shares of common stock are being offered by Immune Design.

• Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin's Lymphoma

  10/20/2017

  G100 is a product candidate from Immune Design's GLAAS discovery platform.

• Immune Design Announces Positive FDA Feedback on Phase III Clinical Trial Design for CMB305 in Synovial Sarcoma Patients

  10/17/2017

  The company plans to initiate a pivotal Phase 3 trial to support a Biologics License Application for CMB305.

• Immune Design Corporation Release: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit And Immune Response

  9/8/2017

• Immune Design Corporation Announces New CMB305 + Checkpoint Inhibitor Topline Data From An Upcoming Presentation At The ESMO 2017 Congress

  8/31/2017

• Immune Design Corporation Announces New CMB305 + Checkpoint Inhibitor Topline Data From An Upcoming Presentation At The ESMO 2017 Congress

  8/31/2017

• Immune Design Corporation Reports Second Quarter 2017 Financial Results And Provides Corporate Update

  8/3/2017

• Immune Design Corporation To Report Second Quarter 2017 Financial Results & Provide Corporate Update

  7/26/2017

• Immune Design Corporation Updates Positive Data From Lead Cancer Immunotherapy Programs At ASCO Annual Meeting

  6/5/2017

• New Clinical And Biomarker Data Validate Immune Design Corporation’s Lead Programs And Discovery Platforms

  5/18/2017

• Immune Design Corporation Reports First Quarter 2017 Financial Results and Provides Corporate Update

  5/18/2017